Sage Journals: Discover world-class research

Abstract

As the AIDS epidemic continues with women being disproportionately affected, it is crucial to understand factors that predict the risk of heterosexual HIV-1 transmission. We investigated whether genital tract viral load (GTVL) in cervical-vaginal lavages (CVL) from HIV-1-positive women with moderately low CD4 T cell counts correlates with cytokine levels, antimicrobial concentrations, and intrinsic anti-HIV activity. CVL were collected from 19 HIV-1-positive women with moderately low CD4 T cell counts [mean 381 cells/mm³ (227–536 cells/mm³)]. None of the women was on antiretroviral therapy. The women were categorized into those with detectable GTVL or those with undetectable GTVL (detectable GTVL RNA levels > 400 copies/ml). Women were also categorized according to bacterial vaginosis (BV) status irrespective of GTVL. The TZM-bl assay was used to determine the presence of infectious virus and anti-HIV activity. Significantly higher levels of RANTES, Eotaxin, Fractalkine, IL-1α, IL-6, MCP-1, MIP1β, MIP1α, TNF-α, and GM-CSF were observed in women with detectable GTVL compared to women with undetectable GTVL. No significant differences were observed in the following cytokines and chemokines: G-CSF, IL-1RA, IL-8, and IP-10. GTVL did not correlate either with antimicrobials known to have anti-HIV activity or with the presence of infectious virus. BV status did not have a significant effect on anti-HIV activity. These findings further our understanding of the role of GTVL in determining the cytokine and chemokine milieu in the female reproductive tract.

Get full access to this article

View all access options for this article.

References

WHO, Women, Health. Today's evidence tomorrow's agenda. http://whqlibdoc.who.int/publications/2009/9789241563857_eng.pdf 2009.

Baeten

et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Translational Med, 2011; 3,77:77ra29.

Mofenson

et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med, 1999; 341,6:385–393.

Anderson

et al. Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis, 2008; 47,9:1216–1221.

Cu-Uvin

. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr, 2006; 42,5:584–587.

McClelland

et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS, 2002; 16,18:2425–2430.

Heffron

et al. Use of hormonal contraceptives, risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis, 2011,11 http://dx.doi.org/10.1016/S1473-3099(11)70247-X.

Clemetson

et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA, 1993; 269,22:2860–2864.

Kovacs

et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet, 2001; 358,9293:1593–1601.

10.

Vernazza

et al. Quantification of HIV in semen: Correlation with antiviral treatment and immune status. AIDS, 1997; 11,8:987–993.

11.

Speck

et al. Risk factors for HIV-1 shedding in semen. Am J Epidemiol, 1999; 150:622–631.

12.

Mostad

. Prevalence and correlates of HIV type 1 shedding in the female genital tract. AIDS Res Hum Retroviruses, 1998; 14:S11–S15.

13.

Kaul

et al. The genital tract immune milieu: An important determinant of HIV susceptibility and secondary transmission. J Reproduct Immunol, 2008; 77,1:32–40.

14.

Cu-Uvin

et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS, 2010; 24,16:2489–2497.

15.

Ghosh

et al. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS ONE, 2010; 5,6:e11366.

16.

Royce

et al. Sexual transmission of HIV. N Engl J Med, 1997; 336,15:1072–1078.

17.

Ghosh

et al. Trappin-2/Elafin: A novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology, 2010; 129,2:207–219.

18.

Gray

et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet, 2001; 357,9263:1149–1153.

19.

Wawer

et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 Infection, in Rakai, Uganda. J Infect Dis, 2005; 191,9:1403–1409.

20.

Wira

et al. Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus. Mucosal Immunol, 2011; 4,3:335–342.

21.

Fahey

et al. Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture. Mucosal Immunol, 2008; 1,4:317–325.

22.

Ghosh

et al. CCL20/MIP3α is a novel anti-HIV-1 molecule of the human female reproductive tract. Am J Reproduct Immunol, 2009; 62,1:60–71.

23.

Shine

et al. Secretory leukocyte protease inhibitor: Inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein. Bioorg Chem, 2002; 30,4:249–263.

24.

Novak

et al. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin. Vaccine Immunol, 2007; 14,9:1102–1107.

25.

Iqbal

et al. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS, 2009; 23,13:1669–1677.

26.

Amsel

et al. Nonspecific vaginitis: Diagnostic criteria and epidemiologic associations. Am J Med, 1983; 74:14–22.

27.

Wei

et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother, 2002; 46,6:1896–1905.

28.

Klotman

, Chang

. Defensins in innate antiviral immunity. Nat Rev Immunol, 2006; 6,6:447–456.

29.

Wira

et al. Innate immunity in the human female reproductive tract: Endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol, 2011; 65,3:196–211.

30.

Venkataraman

et al. cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol, 2005; 175,11:7560–7567.

31.

Cummins

et al. Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method. J Clin Microbiol, 2003; 41,9:4081–4088.

32.

Cummins

et al. Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses, 2006; 22,8:788–795.

33.

Kovacs

et al. HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1. J Acquir Immune Defic Syndr, 1999; 22,2:124–131.

34.

Cohn

et al. HIV-inducing factor in cervicovaginal secretions is associated with bacterial vaginosis in HIV-1-infected women. J Acquir Immune Defic Syndr, 2005; 39,3:340–346.

35.

Olinger

et al. Association of indicators of bacterial vaginosis with a female genital tract factor that induces expression of HIV-1. AIDS, 1999; 13,14:1905–1912.

36.

Shebl

et al. Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retroviruses, 2011(Epub ahead of print)10.1089/aid.2011.0144.

37.

Combadière

et al. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS, 2003; 17,9:1279–1290.

38.

Capobianchi

et al. Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res Hum Retroviruses, 1998; 14,3:233–240.

39.

Cocchi

et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science, 1995; 270,5243:1811–1815.

40.

Iqbal

et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis, 2005; 192,5:728–738.

41.

Asin

et al. HIV type 1 infection in women: Increased transcription of HIV type 1 in ectocervical tissue explants. J Infect Dis, 2009; 200,6:965–972.

42.

Gregory

et al. Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses, 2008; 24,7:973–976.

43.

Poli

et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med, 1990; 172,1:151–158.

44.

Poli

, Fauci

. Cytokine modulation of HIV expression. Sem Immunol, 1993; 5,3:165–173.

45.

Zara

et al. Markers of local immunity in cervico-vaginal secretions of HIV infected women: Implications for HIV shedding. Sex Transm Infect, 2004; 80,2:108–112.

46.

Osborn

, Kunkel

, Nabel

. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA, 1989; 86,7:2336–2340.

47.

Mitchell

et al. Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses, 2011; 27,1:35–39.

48.

Fahey

et al. New approaches to making the microenvironment of the female reproductive tract hostile to HIV. Am J Reprod Immunol, 2011; 65,3:334–343.

49.

Moreau

et al. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie, 2008; 90,2:284–295.

50.

Shaw

, Diamandis

. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology. Biol Chem, 2008; 389,6:681–688.

51.

Shaw

JLV

et al. Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. Biol Chem, 2008; 389,12:1513–1522.

52.

Yamasaki

et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J, 2006; 20,12:2068–2080.

53.

Keller

et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS, 2007; 21,4:467–476.

54.

Al-Harthi

et al. Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J Acquir Immune Defic Syndr, 1999; 21,3:194–202.

55.

Cu-Uvin

et al. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis, 2001; 33,6:894–896.

56.

Taha

et al. HIV infection and disturbances of vaginal flora during pregnancy. J Acquir Immune Defic Syndr Hum Retrovirol, 1999; 20,1:52–59.

Genital Tract Viral Load in HIV Type 1-Positive Women Correlates with Specific Cytokine Levels in Cervical-Vaginal Secretions But Is Not a Determinant of Infectious Virus or Anti-HIV Activity

Abstract

Get full access to this article

References